March 5, 2019 / 6:12 AM / 3 months ago

BRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 15.04 Million

March 5 (Reuters) - Newron Pharmaceuticals SpA:

* FY TOTAL REVENUES DECREASED TO EUR 4.0 MILLION FROM EUR 13.4 MILLION (2017)

* FY CASH USED IN OPERATIONS INCREASED TO EUR 16.1 MILLION (2017: EUR 8.4 MILLION)

* FY NET LOSS 15.035 MILLION EUR VERSUS LOSS 5.282 MILLION EUR YEAR AGO

* EXPECTING THE RESULTS FROM OUR STARS PHASE III STUDY WITH SARIZOTAN IN Q4 2019

* EXPECTS ADDITIONAL APPROVALS AND LAUNCHES OF XADAGO®/SAFINAMIDE DURING 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below